SANUWAVE Health completed the acquisition of a wound care assets of Celularity for $24m.

SANUWAVE Health, a developer of noninvasive, biological response activating devices in the regenerative medicine area, completed the acquisition of a wound care assets of Celularity, a biotechnology company, for $24m. The funding for the acquisition consisted of a mix of funded term debt, a seller note, and equity in the form of a private placement. The private placement generated gross proceeds of approximately $24m through the issuance of 119.125.000 shares of common stock and accompanying warrants to purchase up to an equal number of shares of common stock at a purchase price of $0.2 per share of common stock and accompanying warrants.